We are live on
!
Find out more
IMUC
ImmunoCellular Therapeutics, Ltd.
IMUC
IMUC
Delisted
IMUC was delisted on the 16th of October, 2018.
17 hedge funds and large institutions have $293K invested in ImmunoCellular Therapeutics, Ltd. in 2017 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 5 closing their positions.
New
Increased
Maintained
Reduced
Closed
6% less funds holding
Funds holding: 18 → 17 (-1)
16% less capital invested
Capital invested by funds: $348K → $293K (-$55K)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
Holders
17
Holders Change
-1
Holders Change %
-5.56%
% of All Funds
0.39%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
2
Reduced
3
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
VF
Virtu Financial
New York
|
+$55.2K |
| 2 |
WS
Wedbush Securities
Los Angeles,
California
|
+$8.51K |
| 3 |
Goldman Sachs
New York
|
+$8.23K |
| 4 |
TCM
Tradewinds Capital Management
Bellingham,
Washington
|
+$68 |
Top Sellers
| 1 |
Renaissance Technologies
New York
|
-$30.6K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$23K |
| 3 |
Bank of New York Mellon
New York
|
-$10K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$7.66K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$5K |